JAZZ|Jazz Pharmaceuticals PLC|株価:165.500|変動率:2.35

詳細情報 Jazz Pharmaceuticals PLC 企業名

Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

Jazz Pharmaceuticals PLCの企業情報



企業コードJAZZ

会社名Jazz Pharmaceuticals PLC

上場日Jan 18, 2012

最高経営責任者「CEO」Gala (Renee D)

従業員数2800

証券種類Ordinary Share

決算期末Jan 18

本社所在地Fifth Floor, Waterloo Exchange

都市DUBLIN

証券取引所NASDAQ OMX - NASDAQ BASIC

国Ireland

郵便番号- -

電話番号35316347800

ウェブサイトhttps://www.jazzpharma.com/

企業コードJAZZ

上場日Jan 18, 2012

最高経営責任者「CEO」Gala (Renee D)

Jazz Pharmaceuticals PLCの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Seamus C. Mulligan

Independent Director

1.28M

+3507.00%

Mr. Bruce C. Cozadd

Chairman of the Board

310.79K

+18464.00%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

55.49K

+7370.00%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.68K

+7559.00%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

27.20K

+5577.00%

Mr. Philip L. Johnson

Chief Financial Officer, Executive Vice President

15.00K

--

Dr. Norbert G. Riedel, Ph.D.

Independent Director

13.92K

+1702.00%

Ms. Anne O'Riordan

Independent Director

12.77K

+1702.00%

Ms. Samantha Pearce

Executive Vice President, Chief Commercial Officer

11.28K

+2038.00%

Ms. Jennifer E. Cook

Independent Director

7.11K

+1702.00%

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Seamus C. Mulligan

Independent Director

1.28M

+3507.00%

Mr. Bruce C. Cozadd

Chairman of the Board

310.79K

+18464.00%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

55.49K

+7370.00%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.68K

+7559.00%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

27.20K

+5577.00%

Mr. Philip L. Johnson

Chief Financial Officer, Executive Vice President

15.00K

--

収益内訳

通貨: USD更新時刻: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

Xywav

431.41M

38.31%

Epidiolex/epidyolex

302.61M

26.87%

Rylaze

99.87M

8.87%

Zepzelca

79.30M

7.04%

High-sodium oxybate AG royalty revenue

52.95M

4.70%

他の

159.98M

14.21%

地域別USD

会社名

収益

比率

United States

1.02B

90.62%

Europe

86.41M

7.67%

All Others

19.23M

1.71%

事業別

地域別

事業別USD

会社名

収益

比率

Xywav

431.41M

38.31%

Epidiolex/epidyolex

302.61M

26.87%

Rylaze

99.87M

8.87%

Zepzelca

79.30M

7.04%

High-sodium oxybate AG royalty revenue

52.95M

4.70%

他の

159.98M

14.21%

株主

更新時刻: Thu, Dec 4

株主統計

種類

株主統計

比率

The Vanguard Group, Inc.

9.70%

BlackRock Institutional Trust Company, N.A.

8.25%

Dimensional Fund Advisors, L.P.

4.67%

Capital World Investors

4.20%

LSV Asset Management

4.04%

他の

69.14%

株主統計

比率

The Vanguard Group, Inc.

9.70%

BlackRock Institutional Trust Company, N.A.

8.25%

Dimensional Fund Advisors, L.P.

4.67%

Capital World Investors

4.20%

LSV Asset Management

4.04%

他の

69.14%

種類

株主統計

比率

Investment Advisor

50.55%

Investment Advisor/Hedge Fund

34.46%

Hedge Fund

10.57%

Research Firm

3.49%

Individual Investor

3.09%

Pension Fund

1.75%

Venture Capital

1.30%

Bank and Trust

1.13%

Family Office

0.10%

機関投資家保有株



更新時刻: Thu, Jan 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q4

1196

62.93M

103.56%

-8.99M

2025Q3

1197

64.03M

105.38%

-5.21M

2025Q2

1199

63.76M

105.11%

-6.47M

2025Q1

1235

63.66M

105.15%

-6.35M

2024Q4

1202

62.66M

103.17%

-6.51M

2024Q3

1172

61.48M

99.60%

-6.16M

2024Q2

1167

61.28M

97.21%

-6.97M

2024Q1

1163

63.08M

101.15%

-2.43M

2023Q4

1156

61.76M

98.11%

-3.48M

2023Q3

1158

61.08M

96.76%

-4.05M

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

The Vanguard Group, Inc.

5.88M

9.68%

-184.81K

-3.05%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

5.01M

8.25%

-208.46K

-3.99%

Sep 30, 2025

Dimensional Fund Advisors, L.P.

2.84M

4.67%

+298.81K

+11.77%

Sep 30, 2025

Capital World Investors

2.55M

4.2%

+10.35K

+0.41%

Sep 30, 2025

LSV Asset Management

2.51M

4.13%

-41.88K

-1.64%

Sep 30, 2025

State Street Investment Management (US)

1.87M

3.07%

-67.50K

-3.49%

Sep 30, 2025

EcoR1 Capital, LLC

1.71M

2.81%

--

Sep 30, 2025

JP Morgan Asset Management

1.70M

2.8%

+152.32K

+9.83%

Sep 30, 2025

Fuller & Thaler Asset Management Inc.

1.63M

2.68%

-2.82K

-0.17%

Sep 30, 2025

Columbia Threadneedle Investments (US)

1.57M

2.58%

+29.17K

+1.89%

Sep 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

配当落ち日

種類

比率

データなし

日付

配当落ち日

種類

比率

データなし

Jazz Pharmaceuticals PLC

詳細情報 Jazz Pharmaceuticals PLC 企業名

Jazz Pharmaceuticals PLCの企業情報

Jazz Pharmaceuticals PLCの経営陣

収益内訳

株主

機関投資家保有株

株主動向

関連ETF

配当金

株式分割